Phosphorylation of nitrogen indene, its derivatives, their preparation methods and applications
The indecitazole and phosphite are phosphorylated by electrocatalytic system through electrocatalytic methods, which solves the problems of high temperature and environmental pollution in the prior art, and achieves low-cost, low toxicity and environmentally friendly indecitazole derivatization The synthesis of substances has good anti-cancer cell proliferation activity and high yield.
Patent Information
- Application Number
- CN202410429520.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-10
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-04-10
AI Technical Summary
The existing synthesis methods of indecinidium derivatives have problems such as high temperature, environmental pollution and the use of expensive metal catalysts, and it is difficult to meet the requirements of low cost, low toxicity and environmentally friendly.
By electrocatalytic method, 3-phosphate indecanthine derivatives are prepared by phosphate esterification of indecanthine and phosphite under electrocatalytic system, and electrolytic reactions are carried out using power supply, electrolyte and solvent to achieve green and mild synthesis.
It has achieved safe, non-toxic, low-cost and environmentally friendly preparation of indecinithium derivatives, with good anti-cancer cell proliferation activity and high yield, and is suitable for the preparation of anti-cancer drugs.
Smart Images

Figure CN118207553B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic synthesis, and in particular relates to phosphated indolizine, derivatives thereof, and preparation methods and applications thereof. Background Art
[0002] Indolizine, also known as indolizine. Indolizine derivatives are an important class of nitrogen-containing alkaloids. Related alkaloids can also be isolated from microorganisms, fungi, higher plants, terrestrial and marine animals. In recent years, this class of compounds has shown outstanding performance in cytotoxicity, anti-cancer, anti-bacterial or anti-fungal, antioxidant, immunomodulatory and other biologically active molecules, phospholipase inhibitors, pigments, herbicides, fluorescence properties, etc. The hydrogenated indolizine obtained after its skeleton reduction has been found to be an effective anticancer substance. For example, the indolizine-related substances that have been proven to be effective and widely used include: Swainsonine and Castanospermine (Michael JP Simple Indolizidine and Quinolizidine Alkaloids). Due to the potential properties and applications of this class of substances, the development of new methods for the synthesis of indolizine compounds has received considerable attention.
[0003] Generally, pyridine derivatives are used as substrates in the main synthetic methods of indolizine derivatives in artificial synthetic construction, such as Tschitschibabin condensation, Huisgen reaction, AzaWolff rearrangement and other [3+2]-cycloadditions (PrasadChD, et al. Metal free sulfenylation and bis-sulfenylation of indoles: persulfate mediated synthesis; Nalbandian CJ, et al. A conjugate Lewis base- However, Tschitschibabin condensation, Huisgen reaction, AzaWolff rearrangement and other [3+2]-cycloadditions usually have harsh reaction conditions, such as high temperature, difficult to synthesize raw materials, high environmental pollution, and the need to use expensive metal catalysts, which do not meet the requirements of low cost, low toxicity, and environmental friendliness.
[0004] The invention patent with publication number EP3157920B1 discloses an indolizine derivative as a phosphoinositide 3-kinase inhibitor. The compound defined in the invention inhibits phosphoinositide 3-kinase (PI3K) and can be used to treat diseases related to the PI3K enzyme. The structural formula of the compound defined in the invention is as follows:
[0005]
[0006] Electrocatalytic electrosynthesis is an efficient, environmentally friendly, and highly controllable organic synthesis method with broad application prospects. With the continuous development and improvement of electrocatalysts, electrocatalytic electrosynthesis plays an increasingly important role in various fields. Electrocatalytic transformation is considered to be a promising method for organic synthesis under mild conditions. This method provides a unique direct pathway that can enable the synthesis of molecular structures that are difficult to synthesize using other reaction types. Compared with transition metal catalysts, electrolytes for electrocatalytic reactions have the advantages of low cost, strong synthetic versatility, and non-toxicity and environmental protection.
[0007] At present, there is no disclosure or report on the relevant technology of synthesizing 3-phospho-indolizine derivatives by electrocatalysis. Therefore, the present invention provides a method for preparing phospho-indolizine and its derivatives by electrochemical method, and uses the raw materials and the obtained indolizine derivatives in the preparation of drugs with anti-cancer cell proliferation activity. The preparation method and application of 3-phospho-indolizine derivatives are broadened to obtain more compounds with in vitro anti-cancer cell proliferation activity. Summary of the invention
[0008] The present invention aims at the problems existing in the prior art and provides a phosphated indolizine, its derivatives and a preparation method and application thereof; the present invention provides a new way to prepare 3-phosphated indolizine derivatives with safe and non-toxic raw material sources, electricity as energy source, environmentally friendly reaction conditions, green, mild and efficient. The 3-phosphated indolizine derivatives prepared by the present invention have certain anti-cancer cell proliferation activity and good yield in gram-level reactions, and have potential application prospects in industrial production.
[0009] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0010] First, the present invention provides a method for preparing a 3-phospho-indolizine derivative, the method comprising the steps of: using indolizine as a raw material and phosphite as a sulfur source, and preparing the 3-phospho-indolizine derivative under the action of an electrocatalytic system;
[0011] The synthetic route is as follows:
[0012]
[0013] The structure of the indolizine is shown in Formula 1:
[0014]
[0015] In Formula 1, the R 1 , R 2 Each is independently selected from any one of H, substituted or unsubstituted aryl, alkyl and alkoxy.
[0016] Preferably, the R 1 , R 2 Each is independently selected from any one of H, substituted or unsubstituted aryl, C1-C4 alkyl, and C1-C4 alkoxy.
[0017] More preferably, the R 1 , R 2 Each is independently selected from any one of H, phenyl, substituted or unsubstituted aryl, and C1-C2 alkyl.
[0018] More preferably, the R 1 , R 2 Each independently selected from H, phenyl,
[0019] Any of C1-C2 alkyl groups.
[0020] Preferably, the electrocatalytic system comprises a power source, an electrolyte and a solvent.
[0021] Further preferably, the power supply is a direct current power supply.
[0022] More preferably, the DC power supply has a current of 5-15 mA and a voltage of 10-20 V.
[0023] More preferably, the DC power supply has a current of 10 mA and a voltage of 15 V.
[0024] Preferably, the electrolyte is selected from at least one of tetrabutylammonium hexafluorophosphate, tetrabutylammonium iodide, sodium bromide, and sodium iodide. Further preferably, the electrolyte is selected from at least one of tetrabutylammonium hexafluorophosphate, tetrabutylammonium iodide, and sodium iodide. Even more preferably, the electrolyte is tetrabutylammonium hexafluorophosphate.
[0025] Preferably, the solvent is selected from at least one of 1,2-dichloroethane, dimethyl sulfoxide, acetonitrile, N,N-dimethylformamide, dichloromethane and water.
[0026] More preferably, the solvent is selected from at least one of 1,2-dichloroethane, dimethyl sulfoxide, acetonitrile, N,N-dimethylformamide and dichloromethane.
[0027] More preferably, the solvent is selected from at least one of dimethyl sulfoxide, acetonitrile, N,N-dimethylformamide and dichloromethane.
[0028] More preferably, the solvent is selected from at least one of dimethyl sulfoxide, acetonitrile and N,N-dimethylformamide.
[0029] Most preferably, the solvent is N,N-dimethylformamide.
[0030] Preferably, the structural formula of the 3-phosphorylated indolizine derivative is as shown in Formula 2:
[0031]
[0032] In Formula 2, the R 3 , R 4 , R 5 Each is independently selected from any one of H, substituted or unsubstituted aryl, ether, alkyl, alkoxy and halogen.
[0033] Further preferably, in Formula 2, the R 3 Selected from ether, methoxy, ethoxy, isopropoxy or butoxy.
[0034] More preferably, in Formula 2, the R 4 Any one selected from H, alkyl, substituted or unsubstituted aryl; more preferably, the alkyl is a C1-C4 alkyl.
[0035] More preferably, in Formula 2, the R 5 is selected from H, alkyl or halogen; more preferably, the alkyl is C1-C4 alkyl.
[0036] More preferably, in Formula 2, the R 5 Selected from H, C1-C4 alkyl or halogen.
[0037] More preferably, the structural formula of the 3-phosphorylated indolizine derivative includes but is not limited to the following structure:
[0038]
[0039] Preferably, the molar ratio of the indolizine to the phosphite is 1:1-6; further preferably, the molar ratio of the indolizine to the phosphite is 1:1-5; further preferably, the molar ratio of the indolizine to the phosphite is 1:1-4; the above molar ratio is further preferably 1:1-3; further preferably 1:1-2.5; further preferably 1:1-2; further preferably 1:1-1.8; further preferably 1:1-1.6; further preferably 1:1.1-1.6; further preferably 1:1.2-1.6; further preferably 1:1.3-1.6; further preferably 1:1.4-1.6.
[0040] Preferably, the molar ratio of the electrolyte to the indolizine is 0.2-1:1; the above molar ratio is more preferably 0.3-1:1; more preferably 0.5-1:1; and more preferably 0.5-0.8:1.
[0041] Preferably, R in the phosphite 3 Any one selected from H, substituted or unsubstituted aryl, ether, alkyl, alkoxy, and halogen.
[0042] Further preferably, R in the phosphite 3 Any one selected from H, substituted or unsubstituted aryl, C1-C4 alkyl, C1-C4 alkoxy, and ether.
[0043] More preferably, R 3 Any one selected from ether, methoxy, ethoxy, isopropoxy and butoxy.
[0044] Then, the present invention provides a 3-phospho-indolizine derivative prepared by the above preparation method, and the structural formula of the 3-phospho-indolizine derivative is shown in Formula 2:
[0045]
[0046] In Formula 2, the R 3 , R 4 , R 5 Each is independently selected from any one of H, substituted or unsubstituted aryl, ether, alkyl, alkoxy and halogen.
[0047] More preferably, in Formula 2, the R 3 Selected from ether, methoxy, ethoxy, isopropoxy or butoxy.
[0048] More preferably, in Formula 2, the R 4Any one selected from H, alkyl, substituted or unsubstituted aryl; more preferably, the alkyl is a C1-C4 alkyl.
[0049] More preferably, in Formula 2, the R 5 is selected from H, alkyl or halogen; more preferably, the alkyl is C1-C4 alkyl.
[0050] More preferably, in Formula 2, the R 5 Selected from H, C1-C4 alkyl or halogen.
[0051] More preferably, the structural formula of the 3-phosphorylated indolizine derivative includes but is not limited to the following structure:
[0052]
[0053]
[0054] Finally, the present invention provides the application of the above 3-phosphorylated indolizine derivatives in the preparation of agricultural chemicals, fluorescent materials, pharmaceuticals, medical treatment and chemical industries.
[0055] Preferably, the application is an application in the preparation of anticancer drugs; further preferably, the application is an application in the preparation of drugs for preventing and treating cancer; even more preferably, the cancers include pancreatic cancer, cervical cancer, colorectal cancer, lung cancer, hepatocellular carcinoma, kidney cancer, gastric cancer and bile duct cancer.
[0056] More preferably, the cancer includes hepatocellular carcinoma and cervical cancer.
[0057] In the present invention, the terms:
[0058] 1. Indolizine: Also known as indolizine, it is a privileged structure commonly used in various small molecule drug discovery programs. Functionalized indolizine has been widely used in natural products and synthetic drugs, which are associated with a wide range of biological activities.
[0059] 2. Electrolyte: Electrolytes are compounds that are dissolved in aqueous solutions or in a molten state and can conduct electricity. According to their degree of ionization, they can be divided into strong electrolytes and weak electrolytes. Strong electrolytes are almost completely ionized, while weak electrolytes are only partially ionized.
[0060] 3. Solvent: A liquid that can dissolve solid, liquid or gaseous solutes to form a solution. Solvents usually have a relatively low boiling point and are easy to evaporate, or can be removed by distillation, leaving behind the dissolved substance. Therefore, solvents cannot react chemically with solutes.
[0061] 4. Tetrabutylammonium hexafluorophosphate: white crystalline powder or block.
[0062] 5. Tetrabutylammonium iodide: white crystalline powder; slightly soluble in water (10g / 100mL) and methanol.
[0063] 6. Sodium bromide: colorless cubic crystals or white granular powder. Sodium bromide is slightly soluble in alcohol and can react with dilute sulfuric acid to produce hydrogen bromide. Under acidic conditions, sodium bromide can be oxidized to release bromine.
[0064] 7. Sodium iodide: It is an inorganic compound with the chemical formula NaI. It is a colorless or white crystal, odorless and soluble in water and ethanol. The aqueous solution darkens when exposed to light and releases iodine.
[0065] 8. IC 50 IC: Also known as half inhibitory concentration, it can be used as an indicator of the anti-tumor activity of a drug. It can indicate the half amount of a drug or inhibitor in inhibiting certain substances such as enzymes, cell receptors or microorganisms. This value can be used to measure the ability of a drug to induce apoptosis. That is, the stronger the induction ability, the lower the value. In apoptosis experiments, IC can be calculated 50 To study the inhibitory effect of drugs on tumor cells.
[0066] Unless otherwise specified, the term "alkyl" as used herein includes branched and straight chain saturated aliphatic hydrocarbon groups having a specified number of carbon atoms, including all isomers. Common abbreviations for alkyl groups, such as methyl, can be represented by "Me" or CH3, ethyl, can be represented by "Et" or CH2CH3, propyl, can be represented by "Pr" or CH2CH2CH3, butyl, can be represented by "Bu" or CH2CH2CH2CH3, etc. For example, "C 1-4 "C1-C4 alkyl" refers to a straight or branched chain alkyl group having a specified number of carbon atoms, including all isomers. 1-4 Alkyl includes n-, iso-, sec- and tert-butyl, n- and iso-propyl, ethyl and methyl. 1-10 "Alkyl" and the like have similar meanings.
[0067] The term "aryl" refers to aromatic mono- and polycyclic carbon ring systems, wherein the individual carbon rings in the polycyclic system are fused or connected to each other by single bonds. Typical aryl groups include phenyl, naphthyl, biphenylene, anthracenyl, furanyl, thienyl, etc.
[0068] The term "alkoxy" refers to straight and branched chain alkyl groups having the indicated number of carbon atoms attached through an oxygen bridge.
[0069] The term "halogen" (or "halo") refers to fluorine, chlorine, bromine, and iodine (alternatively referred to as fluoro (F), chloro (Cl), bromo (Br), and iodo (I)).
[0070] Compared with the prior art, the present invention has the following beneficial effects:
[0071] (1) The raw material source of the present invention is safe and non-toxic, and electricity is used as energy source. The reaction conditions are environmentally friendly, green, mild and efficient, and the present invention provides a new approach for the 3-phosphoesterification of indolizine derivatives for organic chemistry researchers.
[0072] (2) The present invention directly synthesizes 3-phosphoindolizine derivatives by electrocatalysis. The prepared 3-phosphoindolizine derivatives have certain anti-cancer cell proliferation activity and have a good yield in a gram-level reaction.
[0073] (3) The method for preparing 3-phosphoindolizine derivatives by the technical solution of the present invention is simple to operate, does not involve metal, has a wide range of application of reaction substrates, good regional selectivity, and high yield. It can be used to synthesize a series of 3-phosphoindolizine derivatives in a green and efficient manner, and has broad application prospects in agricultural chemicals, drug preparation and fluorescent materials. BRIEF DESCRIPTION OF THE DRAWINGS
[0074] Figure 1 This is the hydrogen spectrum of the compound prepared in Example 1 of the present invention.
[0075] Figure 2 This is the carbon spectrum of the compound prepared in Example 1 of the present invention.
[0076] Figure 3 This is the hydrogen spectrum of the compound prepared in Example 2 of the present invention.
[0077] Figure 4 This is the carbon spectrum of the compound prepared in Example 2 of the present invention.
[0078] Figure 5 This is the hydrogen spectrum of the compound prepared in Example 3 of the present invention.
[0079] Figure 6 This is the carbon spectrum of the compound prepared in Example 3 of the present invention.
[0080] Figure 7 This is the hydrogen spectrum of the compound prepared in Example 4 of the present invention.
[0081] Figure 8 This is the carbon spectrum of the compound prepared in Example 4 of the present invention.
[0082] Fig. 9 This is the hydrogen spectrum of the compound prepared in Example 5 of the present invention.
[0083] Fig.10 This is the carbon spectrum of the compound prepared in Example 5 of the present invention.
[0084] Fig.11 This is the hydrogen spectrum of the compound prepared in Example 6 of the present invention.
[0085] Fig.12 This is the carbon spectrum of the compound prepared in Example 6 of the present invention.
[0086] Fig.13 This is the hydrogen spectrum of the compound prepared in Example 7 of the present invention.
[0087] Fig.14 This is the carbon spectrum of the compound prepared in Example 7 of the present invention.
[0088] Fig.15 This is the hydrogen spectrum of the compound prepared in Example 8 of the present invention.
[0089] Fig.16 This is the carbon spectrum of the compound prepared in Example 8 of the present invention.
[0090] Fig.17 This is the hydrogen spectrum of the compound prepared in Example 9 of the present invention.
[0091] Fig.18 This is the carbon spectrum of the compound prepared in Example 9 of the present invention.
[0092] Fig.19 This is the hydrogen spectrum of the compound prepared in Example 10 of the present invention.
[0093] Fig. 20 This is the carbon spectrum of the compound prepared in Example 10 of the present invention.
[0094] Fig.21 This is the hydrogen spectrum of the compound prepared in Example 11 of the present invention.
[0095] Fig. 22 This is the carbon spectrum of the compound prepared in Example 11 of the present invention.
[0096] Fig.23 This is the hydrogen spectrum of the compound prepared in Example 12 of the present invention.
[0097] Fig.24 This is the carbon spectrum of the compound prepared in Example 12 of the present invention. DETAILED DESCRIPTION
[0098] The following non-limiting examples can make those of ordinary skill in the art understand the present invention more comprehensively, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention according to the disclosed content, and it should also belong to the scope of the present invention. When the embodiment gives a numerical range, it should be understood that, unless otherwise specified in the present invention, the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meanings as those of ordinary skill in the technical field to which the present invention belongs.
[0099] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Products from different manufacturers have no significant effect on the effects.
[0100] The yield was calculated as follows: product molar amount / indolizine molar amount × 100%.
[0101] Product purity detection method: by gas chromatography-mass spectrometry.
[0102] In the following embodiments, the power supply of the electrolytic cell is a DC power supply with a current of 10 mA and a voltage of 15 V.
[0103] Example 1
[0104] 57.93 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 46.22 mg (0.42 mmol) of dimethyl phosphite were placed in a 20 mL undivided electrolytic cell, and N,N-dimethylformamide was added at room temperature. After power was turned on for 10 hours, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then subjected to rapid column chromatography to obtain the target product with a yield of 84% and a purity of >98%.
[0105]
[0106] 1H NMR (400MHz, CDCl3) δ9.08 (d, J=7.2Hz, 1H), 7.59-7.51 (m, 2H), 7.45-7.33 (m, 4H), 7. 02-6.90 (m, 1H), 6.70 (t, J=7.4Hz, 1H), 6.54 (d, J=3.8Hz, 1H), 3.56 (d, J=11.6Hz, 6H). 13C NMR (100MHz, CDCl3) δ140.4 (J=16.4Hz), 137.6 (J=0.1Hz), 135.4, 129.6, 127.6, 127.6 , 127.3, 121.4, 118.4, 111.9, 104.9 (J=229.8Hz), 102.8 (J=12.2Hz), 52.2 (J=5.1Hz).
[0107] Example 2
[0108] 89.74 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 46.22 mg (0.42 mmol) of dimethyl phosphite were placed in a 20 mL undivided electrolytic cell, acetonitrile was added at room temperature, and after 10 hours of power supply, the solution was transferred to a round-bottom flask, spin-dried, and flash column chromatography was performed to obtain the target product with a yield of 78% and a purity of >98%.
[0109]
[0110] 1H NMR (400MHz, CDCl3) δ9.07 (d, J=7.1Hz, 1H), 7.51-7.33 (m, 8H), 7.07-6.91 (m, 3H), 6.69 (t, J=6.8Hz, 1H), 6.52 (d, J=3.4Hz, 1H), 5.12 (s, 2H), 3.58 (d, J=11.6Hz, 6H).
[0111] 13C NMR (100MHz, CDCl3) δ158.3, 140.2 (J=16.7Hz), 137.7 (J=11.1Hz), 136.9, 130.7, 128.5, 127.9, 127.9, 1 27.7, 127.5, 121.4, 118.3, 114.0, 111.7, 104.5 (J=229.5Hz), 102.6 (J=12.3Hz), 69.9, 52.2 (J=5.0Hz).
[0112] Example 3
[0113] 66.93 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 46.22 mg (0.42 mmol) of dimethyl phosphite were placed in a 20 mL undivided electrolytic cell, and N,N-dimethylformamide was added at room temperature. After power was turned on for 10 hours, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then flash column chromatography was performed to obtain the target product with a yield of 87% and a purity of >98%.
[0114]
[0115] 1H NMR (400MHz, CDCl3) δ9.06 (d, J=7.2Hz, 1H), 7.47 (d, J=8.7Hz, 2H), 7.41 (d, J=8.9Hz, 1H), 6.94 (t , J=7.5Hz, 3H), 6.67 (t, J=6.9Hz, 1H), 6.50 (d, J=3.9Hz, 1H), 3.84 (s, 3H), 3.57 (d, J=11.6Hz, 6H).
[0116] 13C NMR (100MHz, CDCl3) δ159.0, 140.2 (J=16.7Hz), 137.7 (J=11.1Hz), 130.7, 127.7, 121.3, 11 8.3 (J=1.5Hz), 113.1, 111.7, 104.5 (J=229.6Hz), 102.6 (J=12.3Hz), 55.1, 52.2 (J=5.0Hz).
[0117] Example 4
[0118] 78.32 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 46.22 mg (0.42 mmol) of dimethyl phosphite were placed in a 20 mL undivided electrolytic cell, and dimethyl sulfoxide was added at room temperature. After power was turned on for 10 hours, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then flash column chromatography was performed to obtain the target product with a yield of 65% and a purity of >98%.
[0119]
[0120] 1H NMR (400MHz, CDCl3) δ9.04 (d, J=7.2Hz, 1H), 7.66 (s, 4H), 7.47 (d, J=8.9Hz, 1H), 7.0 4-6.96 (m, 1H), 6.74 (t, J=6.9Hz, 1H), 6.55 (d, J=3.8Hz, 1H), 3.59 (d, J=11.6Hz, 6H). 13C NMR (100MHz, CDCl3) δ139.2, 138.9 (J=16.7Hz), 137.7 (J=11.0Hz), 130.0, 129.4 (J=22.1Hz), 127.7, 124.6 (J=3.8, 3 .6Hz), 124.3 (J=270.4Hz), 121.7, 118.6 (J=1.4Hz), 112.4, 105.2 (J=170.1Hz), 102.9 (J=12.0Hz), 52.3 (J=5.1Hz).
[0121] Example 5
[0122] 71.42 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 46.22 mg (0.42 mmol) of dimethyl phosphite were placed in a 20 mL undivided electrolytic cell, and N,N-dimethylformamide was added at room temperature. After power was turned on for 10 hours, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then subjected to rapid column chromatography to obtain the target product with a yield of 68% and a purity of >98%.
[0123]
[0124] 1H NMR (400MHz, CDCl3) δ9.01 (d, J=7.2Hz, 1H), 8.26 (d, J=8.8Hz, 2H), 7.71 (d, J=8.8Hz, 2H), 7.48 (d, J= 8.9Hz, 1H), 7.06-6.99 (m, 1H), 6.76 (t, J=7.5Hz, 1H), 6.58 (d, J=3.8Hz, 1H), 3.62 (d, J=11.6Hz, 6H).
[0125] 13C NMR (100MHz, CDCl3) δ147.1, 142.4, 137.9 (J=34.3Hz), 137.9 (J=6.8Hz), 130.5, 127.6 , 122.9, 122.0, 118.8, 112.7, 106.1 (J=388.8Hz), 102.9 (J=11.9Hz), 52.4 (J=5.2Hz).
[0126] Example 6
[0127] 66.93 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 46.22 mg (0.42 mmol) of dimethyl phosphite were placed in a 20 mL undivided electrolytic cell, and N,N-dimethylformamide was added at room temperature. After power was turned on for 10 hours, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then subjected to rapid column chromatography to obtain the target product with a yield of 83% and a purity of >98%.
[0128]
[0129] 1H NMR (400MHz, CDCl3) δ9.07 (d, J=8.1Hz, 1H), 7.44 (d, J=8.9Hz, 1H), 7.34 (d, J=6.5Hz, 2H), 7.29 (dd, J=10.7, 5.0Hz, 1H), 7.17 (d, J=7.1Hz, 1H), 6.99-6.93 (m, 1H), 6.69 (td, J=7.1, 1.4Hz, 1H), 6.53 (d, J=3.8Hz, 1H), 3.57 (d, J=11.6Hz, 6H), 2.40 (s, 3H). 13C NMR (100MHz, CDCl3) δ140.6 (J=16.6Hz), 137.7 (J=11.1Hz), 135.3, 130.4, 128.1, 127.7, 127. 5, 126.8, 121.4, 118.4, 111.9, 104.7 (J=230.1Hz), 102.8 (J=12.3Hz), 52.3 (J=5.1Hz), 21.4.
[0130] Example 7
[0131] 75.93 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 46.22 mg (0.42 mmol) of dimethyl phosphite were placed in a 20 mL undivided electrolytic cell, and N,N-dimethylformamide was added at room temperature. After power was turned on for 10 hours, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then subjected to rapid column chromatography to obtain the target product with a yield of 91% and a purity of >98%.
[0132]
[0133] 1H NMR (400MHz, CDCl3) δ9.10 (d, J=6.7Hz, 1H), 7.42 (d, J=8.5Hz, 1H), 7.18-7.08 (m, 2H), 6.99-6 .89 (m, 2H), 6.69 (d, J=6.6Hz, 1H), 6.53 (s, 1H), 3.91 (d, J=2.9Hz, 6H), 3.58 (d, J=11.5Hz, 6H).
[0134] 13C NMR (100MHz, CDCl3) δ148.5, 148.0, 140.3 (J=16.5Hz), 137.8 (J=11.2Hz), 128.0, 127.8, 121.9, 121 .5, 118.4, 113.3, 111.8, 110.5, 104.5 (J=229.7Hz), 102.6 (J=12.3Hz), 55.8, 55.8, 52.3 (J=5.1Hz).
[0135] Example 8
[0136] 62.13 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 46.22 mg (0.42 mmol) of dimethyl phosphite were placed in a 20 mL undivided electrolytic cell, and N,N-dimethylformamide was added at room temperature. After power was turned on for 10 hours, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then flash column chromatography was performed to obtain the target product with a yield of 77% and a purity of >98%.
[0137]
[0138] 1H NMR (400MHz, CDCl3) δ8.95 (d, J=7.1Hz, 1H), 7.55 (dd, J=7.8, 1.1Hz, 2H), 7.42-7.34 (m, 3H), 6.78 ( d, J=6.7Hz, 1H), 6.65 (t, J=6.9Hz, 1H), 6.53 (d, J=4.0Hz, 1H), 3.56 (d, J=11.6Hz, 6H), 2.44 (s, 3H).
[0139] 13C NMR (100MHz, CDCl3) δ140.1 (J=16.6Hz), 138.5 (J=10.8Hz), 135.6, 129.7, 127.6, 127.6, 1 27.4, 125.5, 120.6, 112.1, 105.3 (J=229.5Hz), 101.5 (J=12.4Hz), 52.2 (J=5.0Hz), 18.2.
[0140] Example 9
[0141] 66.34 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 46.22 mg (0.42 mmol) of dimethyl phosphite were placed in a 20 mL undivided electrolytic cell, and N,N-dimethylformamide was added at room temperature. After power was turned on for 10 hours, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then flash column chromatography was performed to obtain the target product with a yield of 79% and a purity of >98%.
[0142]
[0143] 1H NMR (400MHz, CDCl3) δ8.89 (s, 1H), 7.52 (dt, J=5.5, 2.1Hz, 2H), 7.41-7.33 (m, 4H), 6.89 (d, J=9.1H z, 1H), 6.48 (d, J=4.3Hz, 1H), 3.56 (d, J=11.6Hz, 6H), 2.63 (q, J=7.5Hz, 2H), 1.27 (t, J=7.6Hz, 3H).
[0144] 13C NMR (100MHz, CDCl3) δ140.1 (J=16.7Hz), 136.8 (J=11.2Hz), 135.7, 129.6, 127.8, 127.6, 127 .3, 124.7, 123.6, 118.1, 105.9 (J=51.4Hz), 102.5 (J=12.3Hz), 52.2 (J=5.2Hz), 26.2, 15.1.
[0145] Example 10
[0146] 57.93 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 57.98 mg (0.42 mmol) of diethyl phosphite were placed in a 20 mL undivided electrolytic cell, and N,N-dimethylformamide was added at room temperature. After power was turned on for 10 hours, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then subjected to rapid column chromatography to obtain the target product with a yield of 86% and a purity of >98%.
[0147]
[0148] 1H NMR (400MHz, CDCl3) δ9.14 (d, J=8.0Hz, 1H), 7.56 (dd, J=8.1, 1.4Hz, 2H), 7.46-7.32 (m, 4H), 6.95 (dd, J=9.1, 7.0Hz, 1H), 6.68 (td, J=7.1, 1.3Hz, 1H), 6.54 (d, J=3.7Hz, 1H), 4.08-3.98 (m, 2H), 3.92-3.78 (m, 2H), 1.09 (t, J=7.1Hz, 6H).
[0149] 13C NMR (100MHz, CDCl3) δ140.0 (J=16.4Hz), 137.4 (J=10.9Hz), 135.5, 129.8, 127.7, 127.6, 127.3 , 121.2, 118.4, 111.7, 106.0 (J=228.0Hz), 102.6 (J=12.1Hz), 61.8 (J=4.9Hz), 15.8 (J=7.4Hz).
[0150] Embodiment 11
[0151] 57.93 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 69.75 mg (0.42 mmol) of diisopropyl phosphite were placed in a 20 mL undivided electrolytic cell, and N,N-dimethylformamide was added at room temperature. After power was turned on for 10 hours, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then subjected to rapid column chromatography to obtain the target product with a yield of 82% and a purity of >98%.
[0152]
[0153] 1H NMR (400MHz, CDCl3) δ9.21 (d, J=7.2Hz, 1H), 7.66-7.58 (m, 2H), 7.37 (tt, J=14.4, 8.1Hz, 4H), 6.98-6.90 (m, 1H), 6.6 7 (t, J=6.3Hz, 1H), 6.54 (d, J=3.7Hz, 1H), 4.57 (td, J=12.4, 6.2Hz, 2H), 1.27 (d, J=6.2Hz, 6H), 1.00 (d, J=6.2Hz, 6H).
[0154] 13C NMR (100MHz, CDCl3) δ139.7 (J=16.3Hz), 137.1 (J=11.0Hz), 135.9, 130.0, 127.8, 127.6, 127.1, 120.9, 1 18.4, 111.5, 107.3 (J=229.0Hz), 102.6 (J=12.1Hz), 70.9 (J=5.2Hz), 23.9 (J=14.0Hz), 23.4 (J=5.2Hz).
[0155] Example 12
[0156] 57.93 mg (0.3 mmol) of indolizine, 92.98 mg (0.24 mmol) of tetrabutylammonium hexafluorophosphate, and 81.53 mg (0.42 mmol) of di-n-butyl phosphite were placed in a 20 mL undivided electrolytic cell, and N,N-dimethylformamide was added at room temperature. After power was turned on for 10 hours, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then subjected to rapid column chromatography to obtain the target product with a yield of 85% and a purity of >98%.
[0157]
[0158] 1H NMR (400MHz, CDCl3) δ9.14 (d, J=8.0Hz, 1H), 7.56 (dd, J=8.1, 1.4Hz, 2H), 7.46-7.32 (m, 4H), 6.95 (dd, J=9.1, 7.0Hz, 1H), 6.68 (td, J=7.1, 1.3Hz, 1H), 6.54 (d, J=3.7Hz, 1H), 4.08-3.98 (m, 2H), 3.92-3.78 (m, 2H), 1.09 (t, J=7.1Hz, 6H).
[0159] 13C NMR (100MHz, CDCl3) δ140.0 (J=16.4Hz), 137.4 (J=10.9Hz), 135.5, 129.8, 127.7, 127.6, 127.3 , 121.2, 118.4, 111.7, 106.0 (J=228.0Hz), 102.6 (J=12.1Hz), 61.8 (J=4.9Hz), 15.8 (J=7.4Hz).
[0160] The above data show that the yield of the 3-phosphoindolizine derivative prepared by the preparation method provided in the present application is between 65% and 91%, which has a relatively high yield. When the raw material is 2-(3,4-dimethoxyphenyl)indolizine and the phosphorus source is dimethyl phosphite, the yield of the obtained target product is the highest, with a yield of up to 91%.
[0161] Figure 1-Figure 24 The hydrogen spectra and carbon spectra of the compounds prepared in Examples 1 to 12 are given respectively, and the abscissa in the figure is f1 (ppm).
[0162] Comparative Example 1
[0163] The difference from Example 7 is that the direct current conditions used are different, the current is 5 mA, and the voltage is 6 V. The rest is the same as Example 7. The yield is 57%.
[0164] Comparative Example 2
[0165] The difference from Example 7 is that the solvent used is different, and is replaced by ethanol. The rest is the same as Example 7. The yield obtained is 24%.
[0166] Comparative Example 3
[0167] The difference from Example 7 is that the molar ratio of indolizine to phosphite is different. In this comparative example, the molar ratio of indolizine to phosphite is 1:0.5, that is, 0.3 mmol of indolizine and 0.15 mmol of dimethyl phosphite. The rest is the same as Example 7. The yield is 28%.
[0168] Comparative Example 4
[0169] The difference from Example 7 is that the molar ratio of electrolyte to indolizine is different. In this comparative example, the molar ratio of electrolyte to indolizine is 0.1:1, i.e., 0.03 mmol of tetrabutylammonium hexafluorophosphate and 0.3 mmol of indolizine. The rest is the same as Example 7. The yield is 43%.
[0170] Example 5
[0171] Different from Example 7, the preparation was carried out by a traditional method. The specific preparation method was as follows: 75.93 mg (0.3 mmol) of indolizine, 46.22 mg (0.42 mmol) of dimethyl phosphite, and 176.95 mg (0.66 mmol) of manganese acetate dihydrate were placed in a test tube, acetonitrile was added, and the mixture was heated to 100 ° C. for 12 hours. After the reaction was completed, the mixture was extracted with ethyl acetate, and the organic phase was transferred to a round-bottom flask, spin-dried, and then subjected to rapid column chromatography to obtain the target product with a yield of 78% and a purity of >98%.
[0172] Experimental Example 1 MTT test
[0173] The products of Examples 2, 4, 7 and 12 were subjected to MTT test, and the cells selected were HepG2 (human liver cancer cells, derived from Guangzhou Medical University) and HeLa (cervical cancer cells, derived from Guangzhou Medical University).
[0174] The specific operation method is as follows:
[0175] (1) Cell recovery, culture and subculture
[0176] After taking the frozen cells out of the refrigerator, quickly place them in a 37.5℃ constant temperature water bath to thaw, then add the thawed cells to a centrifuge tube containing 1mL DMEM (Gibco brand) in a clean bench, put it in a centrifuge, and centrifuge it at 1000rpm for 3 minutes. After completion, discard the supernatant, add complete culture medium (DMEM culture medium + 10% bovine serum albumin FBS), (bovine serum albumin FBS purchased from ExCell Bio brand). Blow and beat evenly, and take it to a culture bottle. When the color of the culture medium changes, replace the culture medium. When the cells grow to 90% of the culture bottle, pass them on. First, pour out the old culture medium, slowly add 2mL PBS to wash the culture bottle, add 0.5mL trypsin (Tci, derived from porcine pancreas) to digest, and when it is observed that the cells begin to fall off, add culture medium and gently blow until the cells fall off completely. Then collect the cell suspension and centrifuge it at 1000rpm for 3 minutes, discard the supernatant, add complete culture medium, blow and beat evenly, and divide it into two culture bottles.
[0177] (2) MTT method
[0178] Take the logarithmically growing cells, digest them and pipette to evenly distribute the cells, then count the cells and dilute them to 6×10 3 (cell / mL), evenly add 100μL of cell suspension to the 96-well plate (not added to the 36 wells on the edge), place it in the incubator, and give the drug after the cells adhere to the wall for 12 hours. The drug is set to 5 concentrations (90μM, 30μM, 10μM, 3.3μM, 1.1μM, 0μM) and 3 replicates are set. After giving the drug, continue to incubate in the incubator for 48 hours. After the incubation is completed, discard the original solution, add 10μL of MTT solution (5mg / mL) and 90μL of blank culture medium (DMEM culture medium), continue to culture for 4 hours, then discard the original solution, add 100μL of DMSO solution to dissolve, shake on a shaker for 15 minutes, and use an enzyme reader to measure the absorbance value of each well at a wavelength of 490nm. Finally, the cell survival rate is calculated using the following formula:
[0179] Survival rate = (OD test sample - OD blank) / (OD negative control - OD blank) x 100%.
[0180] Negative control: culture medium + cells (no drugs added); blank control: simple culture medium (no cells added).
[0181] IC of analyzed compounds 50The values show that this series of compounds have certain inhibitory activity against the above cell lines. The results of the in vitro anti-cancer cell proliferation activity of each compound are shown in Table 1.
[0182] Table 1
[0183]
[0184] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. A method for preparing a 3-phosphoindolizine derivative, characterized in that: The preparation method comprises the following steps: using indolizine as a raw material and phosphite as a phosphorus source, and preparing a 3-phosphated indolizine derivative under the action of an electrocatalytic system; The electrocatalytic system comprises a power source, an electrolyte and a solvent; The power supply is a DC power supply with a current of 5-15mA and a voltage of 10-20V; The electrolyte is selected from at least one of tetrabutylammonium hexafluorophosphate, tetrabutylammonium iodide, sodium bromide and sodium iodide; The solvent is selected from at least one of 1,2-dichloroethane, dimethyl sulfoxide, acetonitrile, N,N-dimethylformamide, dichloromethane and water; The molar ratio of the indolizine to the phosphite is 1:1-6; the molar ratio of the electrolyte to the indolizine is 0.2-1:1; The synthetic route is as follows: ; The structure of the indolizine is shown in Formula 1: Formula 1; In Formula 1, the R 1 , R 2 Each is independently selected from any one of H, substituted or unsubstituted aryl, alkyl, and alkoxy; The structural formula of the 3-phosphorylated indolizine derivative is shown in Formula 2: Formula 2; In Formula 2, the R 3 is selected from any one of H, substituted or unsubstituted aryl, ether, alkyl, alkoxy, and halogen; said R 4 is selected from any one of H, alkyl, substituted or unsubstituted aryl; said R 5 is selected from H, alkyl or halogen; The R 3 Any one selected from H, substituted or unsubstituted aryl, ether, alkyl, alkoxy and halogen.
2. The preparation method according to claim 1, characterized in that: The R 1 , R 2 Each is independently selected from any one of H, substituted or unsubstituted aryl, C1-C4 alkyl, and C1-C4 alkoxy.
3. The preparation method according to claim 2, characterized in that: The R 1 , R 2 Each independently selected from H, phenyl, , , , , , , , any one of C1-C2 alkyl.
4. The preparation method according to claim 1, characterized in that: The structural formula of the 3-phosphorylated indolizine derivative includes but is not limited to the following structure: 。 5. The preparation method according to claim 1, characterized in that: The molar ratio of the indolizine to the phosphite is 1:1-5; the molar ratio of the electrolyte to the indolizine is 0.3-1:
1.
6. The preparation method according to claim 5, characterized in that: The molar ratio of the indolizine to the phosphite is 1:1-4; the molar ratio of the electrolyte to the indolizine is 0.5-1:
1.
7. The preparation method according to claim 6, characterized in that: The molar ratio of the indolizine to the phosphite is 1:1-3; the molar ratio of the electrolyte to the indolizine is 0.5-0.8:
1.
8. The preparation method according to claim 7, characterized in that: The molar ratio of the indolizine to the phosphite is 1:1-2.
5.
9. The preparation method according to claim 8, characterized in that: The molar ratio of the indolizine to the phosphite is 1:1-2.
10. The preparation method according to claim 9, characterized in that: The molar ratio of the indolizine to the phosphite is 1:1-1.
8.
11. The preparation method according to claim 10, characterized in that: The molar ratio of the indolizine to the phosphite is 1:1-1.
6.
12. The preparation method according to claim 11, characterized in that: The molar ratio of the indolizine to the phosphite is 1:1.1-1.
6.
13. The preparation method according to claim 12, characterized in that: The molar ratio of the indolizine to the phosphite is 1:1.2-1.
6.
14. The preparation method according to claim 13, characterized in that: The molar ratio of the indolizine to the phosphite is 1:1.3-1.
6.
15. The preparation method according to claim 14, characterized in that: The molar ratio of the indolizine to the phosphite is 1:1.4-1.
6.
16. The preparation method according to claim 1, characterized in that: The R 3 Any one selected from H, substituted or unsubstituted aryl, C1-C4 alkyl, C1-C4 alkoxy, and ether.
17. The preparation method according to claim 16, characterized in that: The R 3 Any one selected from ether, methoxy, ethoxy, isopropoxy and butoxy.
18. The 3-phospho-esterified indolizine derivative obtained by the preparation method according to any one of claims 1 to 17, characterized in that: The structural formula of the 3-phosphorylated indolizine derivative is shown in Formula 2: , formula 2; In Formula 2, the R 3 Any one selected from H, substituted or unsubstituted aryl, ether, alkyl, alkoxy, and halogen; The R 4 Any one selected from H, alkyl, substituted or unsubstituted aryl; The R 5 is selected from H, alkyl or halogen.
19. Use of the 3-phosphoindolizine derivative according to claim 18 in the preparation of agricultural chemicals, fluorescent materials, pharmaceuticals, medical treatment and chemical industries.
